Author Archives: Alexis BERNARD

AB Science announces the successful completion of a 2.8 million euros private placement

17/10/2025 – AB Science announces today the successful completion of a capital increase of a total gross amount of EUR 2.8 million subscribed by a limited number of investors

Summary of the virtual conference held on October 16, 2025

16/10/2025 – AB Science provides intitial Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia

AB Science webcast of October 16, 2025

16/10/2025 – Presentation of the AB Science webcast held on October 16, 2025

AB Science will hold a virtual conference on Thursday, October 16, 2025 from 2pm to 3pm CET to provide an update on the Phase 1 study with AB8939

14/10/2025 – The purpose of this virtual conference will be to present in more detail the initial clinical data on the combination of AB8939 + venetoclax in the first three patients with refractory and relapsed AML

Revenues for the first half of 2025 and update on AB Science’s activities

10/10/2025 – AB Science today reports its revenues for the first half of 2025 and provides an update on its activities

AB Science announces a slight delay in the publication of its 2025 half-year financial report

30/09/2025 – The Company will publish its financial report for the first half of 2025 on Friday 10 October, 2025, at the latest

AB Science announces the successful completion of a 2.55 million euros private placement

04/08/2025 – AB Science announces today the successful completion of a capital increase of a total gross amount of EUR 2.55 million subscribed by a limited number of investors

AB Science receives regulatory approval from european countries to initiate third stage of Phase I/II study combining its molecule AB8939 with venetoclax for the treatment of AML

30/07/2025 – AB Science today announced the approval of the third of four stages of the Phase I/II study with the compound AB8939 in adult patients with relapsed/refractory acute myeloid leukemia

AB Science has received approval from several European countries to initiate the confirmatory phase 3 study of masitinib in ALS

24/07/2025 – AB Science today announced that the confirmatory Phase 3 study with masitinib in amyotrophic lateral sclerosis has been authorized by the first set of European countries

AB Science announces the successful completion of a EUR 1.925 million private placement

08/07/2025 – AB Science announces today the successful completion of a capital increase of a total gross amount of EUR 1.925 million subscribed by a limited number of investors